Cellectis (CLLS)

• Market cap: $320M
• 1 day: 1.92%
• 5 days: -3.33%
• 1 month: -16.49%
• 3 months: 19.92%
• 6 months: 108.5%
• Year to date: 76.24%
• 1 year: 82.29%
• 5 years: -82.18%
• 10 years: -92.03%
• Sector: Healthcare
• Industry: Biotechnology

About: Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Employees: 222